Drug · CHEMBL57
NEVIRAPINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. NEVIRAPINE. Drugs and targets, record CHEMBL57. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL57
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- BIRG 0587, BIRG-0587, BIRG0587, NSC-641530, Nevirapina, Nevirapine anhydrous, Nevirapine teva, Nevirapine, anhydrous, Nevirapinum anhydrous
- ChEMBL
- Open Targets' highest stage
- Approval, for 3 of its 11 diseases, from ATC, DailyMed, EMA Human Drugs and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases11
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 11Source Open Targets
See all 11 diseasesTrials179
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01061151 | Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries | Phase 3 | 3,747 | 2018-02-09 | nevirapine | Its name | ClinicalTrials.gov |
| NCT00074581 | Preventing Sexual Transmission of HIV With Anti-HIV Drugs | Phase 3 | 3,526 | 2016-10-31 | nevirapine | Its name | ClinicalTrials.gov |
| NCT00074412 | Using Nevirapine to Prevent Mother-to-Child HIV Transmission During Breastfeeding | Phase 3 | 2,026 | 2013-09-16 | nevirapine | Its name | ClinicalTrials.gov |
| NCT00099359 | Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission | Phase 3 | 1,735 | 2012-12-04 | nevirapine | Its name | ClinicalTrials.gov |
| NCT00561925 | VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients | Phase 3 | 1,068 | 2012-01-19 | nevirapine | Its name | ClinicalTrials.gov |
| NCT00255840 | Evaluation of Two Anti-HIV Treatment Strategies in Resource-Limited South African Communities | 812 | 2011-06-16 | nevirapine | Its name | ClinicalTrials.gov | |
| NCT00089505 | NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission | Phase 3 | 745 | 2011-02-04 | nevirapine | Its name | ClinicalTrials.gov |
| NCT00389207 | Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults | Phase 3 | 576 | 2012-03-26 | nevirapine | Its name | ClinicalTrials.gov |
| NCT00099632 | Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy | Phase 2 | 484 | 2012-01-19 | nevirapine | Its name | ClinicalTrials.gov |
| NCT00307151 | Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV | Phase 2 | 452 | 2011-08-03 | nevirapine | Its name | ClinicalTrials.gov |
1 to 10 of 179
See all 179 trialsComparisons in its trials26
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Early-ART vs Delayed-ART: serious adverse events | 526 of 886 | 522 of 877 | 1,763 | NCT00074581 | Trial comparisons |
| Nevirapine vs Placebo: serious adverse events | 152 of 758 | 141 of 761 | 1,519 | NCT00074412 | Trial comparisons |
| Antiretroviral Therapy Monitored by Medical Officer vs Antiretroviral Therapy Managed by Primary Health Care Nurse: serious adverse events | 126 of 408 | 153 of 404 | 812 | NCT00255840 | Trial comparisons |
| Nevirapine Immediate Release (NVP IR) vs Nevirapine Extended Release (NVP XR): Occurence of Hepatic Events | 0 of 148 | 1 of 295 | 443 | NCT00819052 | Trial comparisons |
| Nevirapine Immediate Release (NVP IR) vs Nevirapine Extended Release (NVP XR): serious adverse events | 33 of 148 | 73 of 295 | 443 | NCT00819052 | Trial comparisons |
| Group 1 vs Group 2: serious adverse events | 11 of 84 | 9 of 86 | 170 | NCT00978068 | Trial comparisons |
| Nevirapine (NVP) Plus Truvada vs Atazanavir Plus Ritonavir (ATV/r) Plus Truvada: Proportion of Patients Reporting CNS Side Effects of Any Severity | 25 of 75 | 23 of 77 | 152 | NCT00552240 | Trial comparisons |
| Nevirapine (NVP) Plus Truvada vs Atazanavir Plus Ritonavir (ATV/r) Plus Truvada: Proportion of Patients Reporting Rash of Any Severity | 21 of 75 | 19 of 77 | 152 | NCT00552240 | Trial comparisons |
Nevirapine (NVP) Plus Truvada vs Atazanavir Plus Ritonavir (ATV/r) Plus Truvada: AIDS Progression and Death: Number of Patients With a Treatment-emergent AIDS Defining Illness or an AIDS-defining Illness Leading to Death | 1 of 75 | 3 of 77 | 152 | NCT00552240 | Trial comparisons |
| Nevirapine (NVP) Plus Truvada vs Atazanavir Plus Ritonavir (ATV/r) Plus Truvada: Proportion of Patients Reporting Hepatic Events of Any Severity | 5 of 75 | 24 of 77 | 152 | NCT00552240 | Trial comparisons |
1 to 10 of 26
See all 26 comparisons in its trialsPapers from its trials304
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials3
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Digit Span Test | 1 | 0 | ConductCognition |
| Matrix Reasoning | 1 | 0 | ConductCognition |
| Simple Reaction Time | 1 | 1 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL57
GET https://conductscience.org/api/drugs/v1/CHEMBL57/trials?page=2